Reevaluation of treatment guidelines for Old and New World leishmaniasis is urgently
needed on a global basis because treatment failure is an increasing problem. Drug …

Leishmaniasis is a zoonotic disease in humans caused by the bite of a parasite-infected
sandfly. The disease, widely referred to as “poor man's disease,” affects millions of people …

Miltefosine is an alkylphosphocholine drug with demonstrated activity against various
parasite species and cancer cells as well as some pathogenic bacteria and fungi. For 10 …

In pharmaceutical formulations, phospholipids obtained from plant or animal sources and
synthetic phospholipids are used. Natural phospholipids are purified from, eg, soybeans or …

Background There are 500,000 cases per year of visceral leishmaniasis, which occurs
primarily in the Indian subcontinent. Almost all untreated patients die, and all the effective …

The control of Leishmania infections relies primarily on chemotherapy. The arsenal of drugs
available for treating Leishmania infections is limited and includes pentavalent antimonials …

Although three new drugs or drug formulations, liposomal amphotericin B (AmBisome),
miltefosine and paromomycin should be available for the treatment of visceral leishmaniasis …

ABSTRACT Miltefosine (hexadecylphosphocholine [HePC]) has proved to be a potent oral
treatment for human visceral leishmaniasis due to Leishmania donovani. The molecular …

Leishmaniasis is a parasitic disease caused by hemoflagellate, Leishmania spp. The
parasite is transmitted by the bite of an infected female phlebotomine sandfly. The disease is …

Miltefosine causes leishmanial death, but the possible mechanism (s) of action is not known.
The mode of action of miltefosine was investigated in vitro in Leishmania donovani …